Target intelligence / Profile preview

RUN and FYVE domain-containing protein 3 (RUFY3)

Target
RUFY3
Molecular classification
Cytoskeletal adaptor protein, Endosomal trafficking protein, FYVE domain-containing protein, RUN domain-containing protein
01

Overview

RUN and FYVE domain-containing protein 3 (RUFY3) is a member of the RUFY protein family, defined by an N-terminal RUN domain and a C-terminal FYVE domain in some isoforms, with the classic neuronal isoform lacking the FYVE domain[1][2]. RUFY3 plays crucial roles in endosomes and lysosome positioning, organelle trafficking, cytoskeletal rearrangements, axonogenesis, and cellular migration, particularly in neuronal and immune cells. Alternative splicing yields distinct tissue-specific isoforms: the neuronal (nRUFY3) version involved in axonal growth and polarity, and the immune-specific (iRUFY3) version that regulates endo-lysosomal positioning and immune cell migration[1]. Dysregulated RUFY3 expression is implicated in cancer cell motility and neurodevelopmental processes, but its direct involvement as a therapeutic target is primarily mechanistic, modulating processes rather than acting as a receptor or enzyme directly targeted by drugs[1][2][3].

Other names
Rap2-interacting protein X (RIPX)Single axon-related protein 1 (Singar1)RUFY3_HUMAN
02

Mechanism of action

Not specifically established for drugs, as RUFY3 is an adaptor/scaffold protein; when dysregulated, may alter cell migration, cytoskeleton dynamics, and organelle trafficking

03

Biological functions

Regulation of endosomal and lysosomal trafficking, especially in immune cells and neuronsNeuronal polarity and axonogenesisCell migration and cytoskeletal dynamicsModulation of antigen presentation in immune cellsAutophagy
04

Disease associations

Cancer (notably gastric cancer cell migration and invasion)Neurodevelopment and neurodegenerative diseasesImmunity (regulation of immune cell responses and phagosome/endosome dynamics)
05

Safety considerations

Impairment of neuronal polarityImpairment of axon growthImpairment of immune responses
06

Biomarkers

Upregulation detected in activated immune cellsUpregulation detected in migration/invasion of certain cancer cells

Beyond the preview

Go deeper on RUN and FYVE domain-containing protein 3 (RUFY3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RUN and FYVE domain-containing protein 3 (RUFY3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call